Photo of Anna Farago,  MD, PhD

Anna Farago, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000
Fax: (617) 726-0453


afarago@partners.org

Anna Farago, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Assistant, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am an Assistant in Medicine within the division of Hematology/Oncology at Massachusetts General Hospital (MGH). I work in the Center for Thoracic Cancers, where I care for patients with lung cancer and other thoracic malignancies. I devote approximately 25% of my full time effort to clinical work, and the remaining 75% to research.

I perform clinical and translational research in lung cancer. My research is largely focused on developing new therapies for high-grade neuroendocrine lung cancers, including small cell lung cancer (SCLC) and large cell neuroendocrine cancer. My translational research stems from my post-doctoral training in the laboratory of Dr. Tyler Jacks at Massachusetts Institute of Technology, where I applied a genetically engineered mouse model of SCLC to develop a preclinical therapeutic pipeline. This involved initiating tumors in mice via conditional deletion of the tumor suppressor genes p53 and Rb1 occurs in the pulmonary epithelium, monitoring tumor growth using in vivo imaging techniques, and treating animals with therapeutic compounds to assess tumor response. I continue to work in this area with an ongoing therapeutic project assessing the activity of combination BH3 mimetic and TORC inhibition therapies, and am also currently developing an allograft system for expanding tumors in immune competent hosts. At MGH, I am working collaboratively with the Engelman laboratory to develop improved preclinical models of SCLC. I will also be involved in clinical trial research at MGH. I am deeply committed to developing new and improved therapies that translate to meaningful improvements in outcomes for patients with lung cancer.

Publications

Powered by Harvard Catalyst
  • Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson A, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1). 2017. PubMed
  • Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther 2017. PubMed
  • Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz K, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis. Clin Cancer Res 2016. PubMed
  • Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SI, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2015. PubMed
  • Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, DuPage M, Tammela T, Kerper NR, Farago AF, Robbins R, Crowley DM, Bronson RT, Jacks T. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity 2015; 43:579-90. PubMed
  • Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A 2015; 112:E1288-96. PubMed
  • McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, Bhutkar A, McKenna A, Dooley A, Vernon A, Sougnez C, Malstrom S, Heimann M, Park J, Chen F, Farago AF, Dayton T, Shefler E, Gabriel S, Getz G, Jacks T. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014; 156:1298-311. PubMed
  • Farago AF, Snyder EL, Jacks T. SnapShot: Lung cancer models. Cell 2012; 149:246-246.e1. PubMed
  • Jensen P, Farago AF, Awatramani RB, Scott MM, Deneris ES, Dymecki SM. Redefining the serotonergic system by genetic lineage. Nat Neurosci 2008; 11:417-9. PubMed
  • Farago AF, Awatramani RB, Dymecki SM. Assembly of the brainstem cochlear nuclear complex is revealed by intersectional and subtractive genetic fate maps. Neuron 2006; 50:205-18. PubMed
  • Landsberg RL, Awatramani RB, Hunter NL, Farago AF, DiPietrantonio HJ, Rodriguez CI, Dymecki SM. Hindbrain rhombic lip is comprised of discrete progenitor cell populations allocated by Pax6. Neuron 2005; 48:933-47. PubMed
  • Meneely PM, Farago AF, Kauffman TM. Crossover distribution and high interference for both the X chromosome and an autosome during oogenesis and spermatogenesis in Caenorhabditis elegans. Genetics 2002; 162:1169-77. PubMed
Hide